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The Inflammatory Bowel Disease Questionnaire in
Randomized Controlled Trials of Treatment for Ulcerative
Colitis: Systematic Review and Meta-Analysis
Aaron Yarlas, PhD,1 Stephen Maher, PhD,1 Martha Bayliss, MA,1 Andrew Lovley, MA,1 Joseph C.
Cappelleri, PhD,2 Andrew G. Bushmakin, MS,2 Marco D. DiBonaventura, PhD2
1

Optum Patient Insights, Optum, Inc., Johnston, RI; 2Pfizer Inc., New York, NY

Purpose

The 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) is the most frequently used
instrument to capture disease-specific quality of life in randomized clinical trials for ulcerative colitis.
This review and meta-analysis provides the first synthesis of evidence regarding the sensitivity of
IBDQ-32 total and domain scores to treatment efficacy.

Methods

 systematic literature search and risk-of-bias assessment yielded 14 articles that were included in the
A
primary analysis. Treatments were categorized as efficacious if they met the primary efficacy endpoint
(which was not the IBDQ-32); otherwise they were categorized as non-efficacious. A continuous
measure of treatment efficacy was calculated for each primary efficacy endpoint. Meta-analysis using
random-effects models compared standardized mean differences in IBDQ-32 total and domain change
scores between target dose and control arms. Meta-regression compared the association between
treatment efficacy and these outcomes.

Results

 tudies with efficacious treatments showed larger mean improvements relative to controls in IBDQS
32 total scores and all 4 domains (Hedges’ g range: 0.49 to 0.67; P<0.001 for all). At the same time,
patients in studies with non-efficacious treatments showed small and nonsignificant improvements in
these outcomes relative to controls (Hedges’ g range: 0.05 to 0.23; P>0.09 for all). Meta-regression
models showed that the magnitude of treatment efficacy was a positive predictor of these same
IBDQ-32 outcomes.

Conclusions

 hese analyses found that IBDQ-32 scores are sensitive to treatment. The results provided here
T
support the use of the IBDQ-32 to capture treatment benefits on quality of life for patients with
ulcerative colitis. (J Patient Cent Res Rev. 2020;7:189-205.)
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U

lcerative colitis (UC) — one of the two major
subtypes of inflammatory bowel disease
(IBD), the other being Crohn’s disease — is
characterized by chronic inflammation and ulceration
of tissue within the colon. UC is a relapse-remittent
disease, such that patients with UC experience
intermittent episodes (flares) that are accompanied
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by clinical symptoms, including abdominal pain
or cramping, fatigue, diarrhea, rectal bleeding, and
frequent and unpredictable urges to defecate. In the
United States, the prevalence of UC has been estimated
at 28.63 with an annual incidence of 1.22 (both per
10,000).1 The presence and severity of active UC is
associated with impaired health-related quality of life
(HRQoL).2-5
In clinical trials of treatments for UC, primary endpoints
are typically disease activity indices, such as the Mayo
score,6 which are based on ratings of frequency and
severity of clinical symptoms and endoscopic activity.
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However, disease activity indices fail to capture the
broader humanistic impact of UC on patients’ physical,
emotional, and social functioning or the humanistic
benefits of treatment. To complement the disease activity
indices, UC trials often include endpoints capturing
change in patients’ HRQoL, with the most frequently
used instrument being the 32-item Inflammatory
Bowel Disease Questionnaire (IBDQ-32).7-9
The IBDQ-32 captures the patient’s experience of IBD
on 4 domains of functioning and well-being: bowel
and systemic symptoms; and emotional and social
function.10 Reviews of the measurement properties
of the IBDQ-32 have found evidence supporting its
reliability, content validity, construct validity, and
responsiveness.7,8,11,12 Further, reviews have concluded
that the IBDQ-32 has the strongest measurement
profile among instruments used to assess IBD-specific
HRQoL.7,8,11 Other reviewers have recommended that
the IBDQ-32 be included as an endpoint in all UC
clinical trials in which HRQoL of patients is a relevant
outcome.9,13
Despite the evidence supporting the reliability, validity,
and responsiveness of the IBDQ-32 when used in
observational or noncomparative treatment studies
of patients with IBD, to our knowledge there are no
comprehensive reviews of the IBDQ-32 when used in
randomized controlled trials of patients with UC. Thus,
there is a lack of evidence speaking to the degree to which
the IBDQ-32 demonstrates sensitivity to treatment.
The objective of this systematic literature review and
meta-analysis was to address this evidence gap by
examining the magnitude of change in mean IBDQ32 scores as a function of treatment efficacy. For this
purpose, treatment efficacy was defined in two ways:
1) dichotomously (efficacious or non-efficacious),
based on whether or not the study’s prespecified
primary efficacy endpoint (based on a clinical measure
of disease activity, not the IBDQ-32) was met; and 2)
continuously, based on the effect size (ES) computed for
the difference in change on the study’s primary efficacy
endpoint between target treatment and control arms.
Results from these analyses will add to the evidence
of the IBDQ-32’s sensitivity to treatment and its
utility as an endpoint for assessing the impact of
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UC treatments on functioning and well-being in
randomized controlled trials. More generally, these
analyses address the important question of how well
patient-centered outcomes of HRQoL used in clinical
research and practice correspond to changes in clinical
health as a function of treatment interventions.

METHODS

Inflammatory Bowel Disease Questionnaire
(IBDQ-32)
The IBDQ-32 was developed in the late 1980s at
McMaster University (Hamilton, Canada).10,14 Item
selection was based on concept elicitation interviews
with patients with UC or Crohn’s disease as well as
clinical experts, followed by cognitive debriefing
among IBD health professionals and patients, resulting
in 32 items.15 All items use 7-point Likert-type scales
for capturing symptom-related experiences over
the previous 2 weeks, with 1 indicating the highest
symptom frequency/severity and 7 indicating the
lowest symptom frequency/severity.
Content analysis led to formation of 4 domains: 1)
bowel symptoms, 2) systemic symptoms, 3) emotional
function, and 4) social function (domain scoring and
characteristics are presented in online-only Supplemental
Table S1). A total score can also be calculated as the
sum of all 32 items (score range: 0–224). Higher
domain and total scores indicate better HRQoL.
Literature Search
A systematic search of the published literature,
which followed Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines,16 identified articles reporting data from
randomized controlled trials in which the IBDQ-32
was administered to adults with active UC. (The search
protocol will be made available upon request to the
authors.) Searches of PubMed, Embase (OvidSP), and
the Cochrane Register of Controlled Trials databases
were first conducted on September 8, 2017. For the
purpose of updating the search results, the search
was repeated on September 25, 2019, with the “date
of publication” terms updated to restrict the search to
newer records that had been published after the first
search had been conducted. Search terms included
“inflammatory bowel disease questionnaire,” “IBDQ,”
“ulcerative colitis,” and “inflammatory bowel disease.”
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Where appropriate, MeSH terms were used for disease
terms (specific terms only, not “exploded”). Articles
were filtered for English language only.
In the original search (2017), the publication date of
articles was restricted from 2003 to present, since
the IBDQ-32 development paper was published in
2003. In the updated search (2019), the publication
date of articles was restricted from 2017 to present to
capture articles published after the original search was
conducted. Articles retrieved from the updated search
that were published in 2017 were manually checked to
remove duplicates of articles that had been retrieved in
the original search. Specific search terms and strings
used within each database are provided in onlineonly Supplemental Figure S1. During full-text review,
potentially relevant articles cited by papers were also
identified for abstract screening.
Inclusion/Exclusion Criteria: To be included in the
review, identified papers needed to describe a doubleblinded randomized controlled trial in which the
IBDQ-32 was administered to adult patients with active
UC before and after the patients had received either
an active treatment or a true control (eg, placebo for
drug studies, conventional care for psychotherapeutic
studies). In addition, articles needed to report IBDQ32 data that afforded calculation of ES estimates
for mean differences in total and/or domain scores.
Finally, the success or failure of treatment to meet the
study’s primary (clinical) efficacy endpoint needed to
be reported in the article or reported for that trial in a
different article for which there was a citation.
Article Screening: Screenings of abstracts and fulltext articles were performed by at least 2 independent
reviewers (from among authors A.Y., S.M., and A.L.)
for each article. Any discrepancy among reviewers in
a selection decision was resolved by discussion among
all 3 reviewers until a consensus decision was reached.
Extraction of Data: Relevant data were extracted
from each selected article by 1 researcher
(from among authors A.Y., S.M., and A.L.) and
independently reviewed for accuracy by at least 1
other researcher. Any discrepancy in extraction was
resolved by discussion among at least 2 researchers
until a consensus decision was reached.
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Values for IBDQ-32 scores reported numerically
in an article were extracted directly and added to a
database. If the IBDQ-32 scores were reported only
graphically in an article (ie, displayed in a figure but
not as numeric values), values were estimated using
the software WebPlotDigitizer-Desktop, Version 2.8
(https://automeris.io/WebPlotDigitizer, Ankit Rohatgi,
San Francisco, CA), which converts the spatial
distance of points on a graph into numeric values.
WebPlotDigitizer has been demonstrated to have high
levels of intercoder reliability and validity when used
for this purpose.17 For all studies, IBDQ-32 scores
were extracted only for the assessment visits at which
the primary efficacy endpoint was evaluated.
Derivation of ES estimates were calculated using
Comprehensive Meta-Analysis (CMA) software,
Version 3.3 (Biostat, Inc., Englewood, NJ).
Risk-of-Bias Assessment
Risk of bias was assessed for each included study to
identify threats to internal validity due to systematic
errors in the design, procedures, or reporting of the
study. The risk of bias tool provided by the Cochrane
Collaboration18 was used to evaluate the severity of
risk (low, high, or unknown) for each study across 6
domains: sequence generation, allocation concealment,
blinding, incomplete outcome data, selective reporting,
and other sources of bias. For studies that did not
report information relevant for assessing risk of bias,
we conducted searches of selected online clinical trial
registries (eg, clinicaltrials.gov, chictr.org.cn) and
performed internet searches for study protocols or
other available documentation.
Any study for which a high risk was not identified for
any of the 6 domains was considered a low-risk-ofbias study; a study with 1 or 2 high-risk domains was
considered a moderate-risk-of-bias study; and a study
with 3 or more high-risk domains was considered to
be a high-risk-of-bias study. To enhance the reliability
of our findings, it was determined that any studies rated
as having high risk of bias would be excluded from the
primary analysis. If the assessment identified 1 or more
studies as having a high risk of bias, a separate sensitivity
analysis, with high-risk-of-bias studies included in metaanalysis models of mean differences in IBDQ-32 total
and domain change scores, would be conducted.
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Analysis Methods
All models focused on establishing the relationship
between treatment arm (active treatment vs control)
and changes in IBDQ-32 scores. Changes in IBDQ32 scores were measured using standardized ES (ie,
Hedges’ g statistic) to allow for comparison across
domains and total scores, which had different scaling.

were calculated for combined treatment arms based
on averaging of means and standard deviations when
weighting for sample size. Treatment effects based on
proportions were calculated for combined treatment
arms by summing the number of subjects who met the
primary endpoint criterion (eg, clinical response) and
summing the number of total subjects.

Two moderator variables also were included in the
primary analyses to establish whether the relationship
between treatment arm and IBDQ-32 score changes
may vary systematically. A dichotomous measure
of treatment efficacy — coded as “efficacious” if the
study’s primary efficacy endpoint was successfully
achieved or as “non-efficacious” if the study’s primary
efficacy endpoint was not achieved — was included as
a categorical moderator in all meta-analysis models. A
continuous measure of treatment efficacy, defined as
the Hedges’ g ES for the comparison of change in the
primary efficacy endpoint between the treatment and
control arms, was included as a continuous moderator
(predictor) in all meta-regression models. (Hedges’
g was calculated directly or estimated using the logit
method,19 as implemented in CMA Version 3.3.20) For
studies using multiple treatment arms (eg, treatment at
different doses), the primary analysis only calculated
treatment efficacy for the treatment arm using the
dosage recommended or approved for use in this
population or, if this information was not available for a
treatment type, the highest dosage administered during
the trial (referred to hereafter as the “target dose”).

For cases in which some treatment arms were
relatively efficacious (vs control) while others
were non-efficacious within the same study, rules
for categorization were used to classify the overall
efficacy of treatment as follows. First, if more than half
of treatment arms were efficacious or non-efficacious,
the category followed the majority of treatment arms.
Second, if there were the same number of efficacious
and non-efficacious treatment arms, a statistical
test similar to those used in the original study (eg,
independent-samples t-test, z-test for difference
in proportions) was conducted, and the statistical
significance of the results of that test (ie, P<0.05) was
used to determine the category of treatment efficacy.

Additional meta-analyses were conducted to examine
effects of other categorical moderating variables on
the magnitude of treatment differences in standardized
mean change (Hedges’ g) for IBDQ-32 scores.20
These additional moderators included treatment type,
treatment duration, and baseline disease severity.
A sensitivity analysis was conducted in which metaanalysis models were tested across all active treatment
arms within each study rather than only the target dose
as in the primary analysis. Studies with a single active
treatment arm were included as in the primary analysis.
However, for studies with multiple active treatment
arms, treatment effects for all combined treatment arms
were simultaneously compared to the control arm.
Treatment effects based on changes in mean scores

192 JPCRR • Volume 7, Issue 2 • Spring 2020

All meta-analyses were conducted using randomeffects models to calculate pooled ES estimates within
each subgroup of the treatment efficacy categorical
moderator (ie, efficacious or non-efficacious treatment)
and to compare ES estimates between subgroups.20
Random-effects models were chosen because inclusion
of different treatment methods across studies led to the
assumption that there could be different “true” ES for
each study.20 Individual treatment comparisons were
weighted within treatment efficacy subgroups using
inverse variance derived from the random-effects
models. Meta-analyses across studies were based on
Hedges’ g ES for standardized differences between
mean total or domain scores. Interpretation of ES
magnitude, both within and across studies, followed
Cohen’s conventions: 0.20 indicated a small effect,
0.50 indicated a medium effect, and 0.80 indicated
a large effect.21 Heterogeneity within subgroups of
studies (ie, efficacious studies, non-efficacious studies)
was assessed using the I2 statistic, which estimates the
percentage of variability due to heterogeneity among
studies rather than sampling error. I2 values of 25%,
50%, and 75% can be interpreted as indicating low,
moderate, and high heterogeneity, respectively.22 Given
the small numbers of studies being compared across
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moderator subgroups, and thus the low statistical
power to detect group differences in ES, statistical
significance for between-groups heterogeneity (ie,
Cochran’s Q test) was tested using α of 0.10, as has
been recommended elsewhere.23-25
Meta-regression models for IBDQ-32 endpoints were
conducted using random-effects models with maximum
likelihood estimation for deriving the coefficient, with
treatment efficacy as the sole continuous predictor
(Hedges’ g ES estimates for efficacy of primary
endpoint) of the treatment difference for mean IBDQ-32
domain or total scores (also Hedges’ g ES estimates).20
Publication bias was examined using a funnel plot
and Egger’s test (with α of 0.05) for the distribution
of Hedges’ g for mean differences in IBDQ-32 total
scores by the standard error observed within each
study reporting this outcome.20
All meta-analyses, meta-regressions, and publication
bias analyses reported here were conducted using
CMA Version 3.3,20 which also was used to generate
the corresponding forest plots and scatterplots.

RESULTS

Literature Search
The PRISMA diagram, which combines results
from the searches conducted in September 2017 and
September 2019, outlines the sources included in the
search, the number of articles retrieved from each
source, and the number of articles excluded at each
stage of the screening process (Figure 1). IBDQ32 data were extracted from 15 articles that met all
criteria for inclusion in this review.26-40 Reasons for
exclusion of articles during abstract screening, fulltext screening, and data extraction are presented in
online-only Supplemental Tables S2–S4, respectively.
Study Characteristics
Sample and design characteristics of studies in the
15 selected articles are presented in Table 1. Several
of these articles included multiple comparisons of
an endpoint due to either reporting of findings from
multiple independent studies, or because arms for more
than one treatment dose were compared to the control
arm. In total, there were 33 treatment arm comparisons
across endpoints, of which 18 included the target dose.
Seven articles30-33,37,38,40 reported findings from biologic

Figure 1. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) diagram.
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Moderate 58 pts with mostly mildto-moderate active UC at
university clinics in Norway &
Germany

Low

High

Boye (2011)27

Cross (2012)28

Elsenbruch
(2005)29

Control

Low

Panaccione
(2014)34

181 pts with moderate-tosevere active UC at medical
centers in Belgium

24 pts with moderateto-severe active UC at a
university hospital in U.K.

Low

Leiper (2011)33

AZA+IFX (n=63)

RTX 1 g (n=16)

VDZ 300 mg (n=225)

12 weeks

AZA-only (n=53) 16 weeks
+ IFX-only
(n=65)

Placebo (n=8)

Placebo (n=149) 6 weeks

Placebo (n=123) 8 weeks

ACT 2: 364 pts with
IFX 5 mg/kg (n=121)
moderate-to-severe active UC
at medical sites globally

895 pts with moderate-tosevere active UC at medical
centers in 34 countries

Placebo (n=121) 8 weeks

6 weeks

10 weeks

Yes (0.70)

No (-0.12)

Yes (1.69)

Yes (0.59)

No (-0.04)

Yes (0.43)

No (0.26)

• Total

• Total

• Total

• Total
• Domains

Table continued on next page

Remission: (TMS < 3)
& (all MS items < 2) &
(No CS use)

Remission:
(TMS < 3)

Response: (TMS
Yes (0.53)
decrease ≥ 3 pts/30%)
& (RB decrease ≥ 1 pt
or RB < 2)

Response: (TMS
Yes (0.81)
decrease ≥ 3 pts/30%)
& (RB decrease ≥ 1 pt
or RB < 2)

• Total
• Domains

• Total

• Total
• Domains

• Total

• Total

• Domains

Efficacy
on Primary
Endpoint? IBDQ
(Hedges’ g) Outcomes

Response: (TMS
Yes (0.74)
decrease ≥ 3 pts/30%)
& (RB decrease ≥ 1 pt
or RB < 2)

TMS

RCAI

12 months Seo index

ACT 1: 364 pts with
IFX 5 mg/kg (n=121)
moderate-to-severe active UC
at medical sites globally

Feagan (2013)32 Low

Ad hoc CAI (bowel
frequency, rectal
bleeding, histology,
sigmoidoscopy)

18 months RCAI (modified)

Feagan (2007)31 Low

Placebo (n=63)

Wait-list control
(n=15)

BAC (n=22)

TAU (n=23)

6 weeks

Treatment Primary Efficacy
Duration Endpoint

181 pts with mild-to-moderate VDZ 2 mg/kg (n=60)
active UC at university
medical centers globally

Mind-body therapy EW
(n=15)

Home telemanagement
(n=25)

Stress management EW
(n=35)

Tinzaparin 175 anti-Xa IU/ Placebo (n=52)
kg/day for 14 days followed
by tinzaparin 4500 anti-XA
IU/day for 28 days (n=48)

Target Treatment

Feagan (2005)30 Low

30 pts with mild active
UC recruited via public
advertisements in Germany

47 pts with mild-to-moderate
UC at a university hospital or
veterans clinic in the U.S.

106 pts with mild-to-moderate
active UC at hospital
outpatient clinics in Europe &
Canada

Low

Bloom (2004)26

Sample

Risk of
Biasa

Author

Table 1. Sample and Study Characteristics of Reviewed Articles
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Low

Sandborn
(2014)40

Placebo (n=252) 6 weeks

Phase III: 761 pts with
GLM 200/100 mg (n=252)
moderate-to-severe active UC
at medical centers globally

6 weeks

Placebo (n=40)

4 weeks

6 weeks

Phase II: 164 pts with
GLM 200/100 mg (n=41)
moderate-to-severe active UC
at medical centers globally

88 pts with mild-to-moderate Repifermin 50 µg/kg (n=14) Placebo (n=28)
UC at medical centers in U.S.

Placebo (n=77)

6 weeks

• Total

No (0.22)

No (0.28)

Response: (TMS
Yes (0.48)
decrease ≥ 3 pts/30%)
& (RB decrease ≥ 1 pt
or RB < 2)

TMS

Remission: (TMS EA = No (-0.75)
0) & (RB = 0) & (SF <
2) & (PGA < 2)

• Total

• Total

• Total

• Total

• Total
• Domains

• Total
• Domains

• Total
• Domains

Yes (0.93)

Yes (0.51)

Response: (TMS
No (0.27)
decrease ≥ 3 pts/30%)
& (RB decrease ≥ 1 pt
or RB < 2)

Remission: (TMS < 3)
or (Baron score = 0)

Remission: (TMS < 3)
& (all MS items < 2) &
(RB = 0)

Remission: (TMS < 3)
& (all MS items < 2) &
(RB = 0)

Response: (TMS
No (0.42)
decrease ≥ 3 pts/30%)
& (RB decrease ≥ 1 pt
or RB < 2)

Efficacy
on Primary
Endpoint? IBDQ
(Hedges’ g) Outcomes

5-ASA, 5-aminosalicylic acid; AZA, azathioprine; BAC, best available care; BID, twice daily; CAI, Colitis Activity Index; CS, corticosteroids; DAI, disease activity index; EA,
endoscopic appearance; EW, every week; GLM, golimumab; IBDQ, Inflammatory Bowel Disease Questionnaire; IFN, interferon-β-1a; IFX, infliximab; IU, international unit;
kg, kilogram; MS, Mayo score; PGA, Physician's Global Assessment; pts, patients; RB, rectal bleeding; RCAI: Rachmilewitz clinical activity index; RTX, rituximab; SF, stool
frequency; TAU, treatment as usual; TMS, total Mayo score; UC, ulcerative colitis; VDZ, vedolizumab.

*Data in the meta-analysis were based on those reported in a published erratum to this article.53

Based on number of domains with high risk of bias: 0 = low risk; 1-2 = moderate risk; 3 or more = high risk. High risk of bias studies were excluded from the primary analysis.

a

Low

Sandborn
(2003)39

GLM 4 mg/kg (n=77)

291 pts with moderate-tosevere active UC at medical
centers globally

Low

Placebo (n=20)

Placebo (n=112) 8 weeks

OCTAVE Induction 2: 547 pts Tofacitinib 10 mg BID
with moderate-to-severe active (n=429)
UC at medical sites globally

8 weeks

Treatment Primary Efficacy
Duration Endpoint

Placebo (n=122) 8 weeks

Placebo (n=48)

Control

OCTAVE Induction 1: 614 pts Tofacitinib 10 mg BID
with moderate-to-severe active (n=476)
UC at medical sites globally

Tofacitinib 10 mg BID
(n=33)

Rutgeerts
(2015)38

Low

Panes (2018)36*

194 pts with moderate-tosevere active UC at medical
centers globally

Target Treatment

43 pts with moderately active, IFX 5 mg/kg (n=23)
glucocorticoid-resistant UC
at medical centers in U.K. &
Germany

Low

Panes (2015)35

Sample

Probert (2003)37 Low

Risk of
Biasa

Author

Table 1 (continued). Sample and Study Characteristics of Reviewed Articles

treatments (golimumab, infliximab, rituximab, or
vedolizumab), 4 articles26,35,36,39 reported small-molecule
treatments (tinzaparin, tofactinib, or repifermin),
2 articles27,29 reported findings from psychological
therapy (stress management or mind-body therapy), 1
article reported treatments of management training,28
and 1 article reported combined small-molecule and
biologic treatment (azathioprine and infliximab).34
Treatment duration, defined as treatment onset through
assessment of the primary efficacy endpoint (and thus
the assessment of IBDQ-32 scores analyzed here),
ranged from 4 to 16 weeks for biologic and smallmolecule treatments, with 6- and 8-week assessments
most commonly used. Treatment duration for studies
using psychological therapy varied from 10 weeks to
18 months, while the efficacy of treatment management
training was assessed after 12 months.
All studies defined their primary efficacy endpoint as
treatment differences in change in a disease activity
index based on clinical and/or endoscopic activity. All
studies used well-established disease activity indices
for use in clinical trials, such as Rachmilewitz’s
clinical activity index,41 Mayo score,6 Seo index,42
and Sutherland’s UC disease activity index,43 with the
exception of one study26 that used an ad hoc disease
activity index capturing clinical, endoscopic, and
histologic activity. Six studies used differences in
mean change on the disease activity index as their
primary endpoint, 6 used differences in proportion
of patients showing clinical response, and 6 used
differences in proportion of patients achieving clinical
and/or endoscopic remission (with the latter two
approaches each using the Mayo score to define
response or remission).
For 11 articles, ES estimates for treatment differences
in mean change scores were calculated directly
from reported numeric data. For the remaining 4
articles,29,31,32,34 ES estimates were calculated from
data extracted from figures using WebPlotDigitizer.
Risk of Bias
The risk-of-bias analysis by individual study (onlineonly Supplemental Figure S2) and across all studies
(online-only Supplemental Figure S3) showed that the
risk of bias was low across most risk-of-bias domains
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and studies. Only 2 of 15 articles described studies
that had 1 or more domains that were judged to have a
high risk of bias: Boye et al27 had 1 high-risk-of-bias
domain and was considered a moderate-risk-of-bias
study; while Elsenbruch et al29 had 3 high-risk-of-bias
domains and thus was considered a high-risk-of-bias
study. Following the prespecified criteria, this latter
study was excluded, leaving 14 articles for the primary
analysis. However, the sensitivity analysis conducted
included the high-risk-of-bias study (and, therefore,
reflected all 15 articles).
Primary Analysis
Of the 14 articles included in the primary analysis,
13 reported differences in mean IBDQ-32 total score
for a total of 16 comparisons that included the target
dose (3 articles31,36,40 each reported results from 2
independent studies in which target dose was used),
and 4 reported differences in mean IBDQ-32 domain
scores for a total of 5 comparisons that included target
dose. Of the 16 comparisons for mean IBDQ-32 total
scores, 10 were categorized as having efficacious
treatments while 6 were categorized as having nonefficacious treatments. Of the 5 comparisons for mean
IBDQ-32 domain scores, 3 were categorized as having
efficacious treatments while 2 were categorized as
having non-efficacious treatments.
Meta-Analyses: Pooled estimates of Hedges’ g for
mean differences in IBDQ-32 total scores (Figure
2, Table 2) were medium-sized (ES: 0.67; 95%
confidence interval [CI]: 0.51, 0.83) and statistically
larger than zero (P<0.001) when summarized across
the 10 efficacious treatments, but were small (ES: 0.23;
95% CI: -0.04, 0.50) and not statistically different from
zero (P=0.09) across the 6 non-efficacious treatments.
The pooled ES estimate was statistically larger for the
efficacious studies than for non-efficacious treatment
(Q(1): 7.5; P=0.006).
High heterogeneity was observed among the 10
efficacious studies (I2=74.1%), whereas little
heterogeneity was observed among the 6 nonefficacious studies (I2=0%). Further examination
indicated that the high heterogeneity among efficacious
studies was not driven by a single outlier; when
removing the study by Cross et al28 — which reported
a much larger treatment effect (ES: 2.02), more than

Review

Figure 2. Forest plot for treatment comparisons of mean differences in Inflammatory Bowel Disease

Questionnaire (IBDQ-32) total scores for efficacious and non-efficacious treatments. Pooled effect estimates were
calculated based on random-effects models, with relative weights for individual comparisons based on inverse
variance. The diamond represents a pooled effect estimate for each treatment efficacy subgroup. Data are Hedges’
g with 95% confidence intervals.

Table 2. Results From Primary Meta-Analysis
Between Subgroups
(Heterogeneity)

Within Subgroups
No. of Studies

Pooled Hedges’ g
(95% CI)

P

I2

Q (df)

P

Non-efficacious
Efficacious

6
10

0.23 (-0.04, 0.50)
0.67 (0.51, 0.83)

0.092
<0.001

0%
74.1%

7.45 (1)

0.006

Bowel
symptoms

Non-efficacious
Efficacious

2
3

0.16 (-0.22, 0.53)
0.58 (0.47, 0.70)

0.404
<0.001

0%
0%

4.51 (1)

0.034

Systemic
symptoms

Non-efficacious
Efficacious

2
3

0.07 (-0.30, 0.45)
0.50 (0.38, 0.61)

0.701
<0.001

0%
0%

4.50 (1)

0.034

Emotional
function

Non-efficacious
Efficacious

2
3

0.10 (-0.27, 0.47)
0.49 (0.37, 0.60)

0.600
<0.001

0%
0%

3.82 (1)

0.051

Social
function

Non-efficacious
Efficacious

2
3

0.05 (-0.32, 0.42)
0.55 (0.44, 0.67)

0.793
<0.001

0%
0%

6.41 (1)

0.011

Endpoint

Efficacy Subgroup*

Total score

*Efficacious treatments are those which achieved their primary endpoint; non-efficacious treatments are those for which the
primary endpoint was not met.
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twice as large as the other studies in this category —
there remained substantial heterogeneity among the 9
remaining studies (I2=61.9%). (Even with the removal
of this study from the model, the pooled ES for the 9
remaining efficacious studies [ES: 0.62, 95% CI: 0.48,
0.75] was still statistically significantly greater than for
the non-efficacious studies [ES: 0.24; 95% CI: 0.00,
0.47]; Q(1): 7.5; P=0.006.)
Pooled estimates of Hedges’ g for mean differences
in each of the IBDQ-32 domain scores (Figures 3–6,
Table 2) were medium-sized (ES range: 0.49 to 0.58)
and statistically larger than zero (P<0.001 for all)
when summarized across the 3 efficacious treatments,
but were very small (ES range: 0.05 to 0.16) and not
statistically different from zero (P>0.10 for all) across
the 2 non-efficacious treatments. The pooled ES
estimate was statistically larger for the efficacious than
non-efficacious studies for all domains (P<0.10 for
all). Little heterogeneity was observed within studies
by efficacy category for domain scores (I2=0% for all).
Meta-Regression:
Regression
coefficients
of
continuous treatment efficacy (Hedges’ g ES) as a
predictor of Hedges’ g for mean differences for each
IBDQ-32 outcome are presented in Table 3. Results
from all models indicate a positive association, such
that increases in the magnitude of treatment efficacy
on the primary efficacy endpoint predict larger mean
differences in IBDQ-32 total and domain scores.
The regression coefficient of 0.71 found for the ES
estimate of treatment efficacy on the primary efficacy
endpoint for IBDQ-32 total scores indicates that a
1-unit increase in the ES estimate (ie, an increase of 1
standard deviation in IBDQ total score) for treatment
differences in mean change of IBDQ-32 total scores
corresponds to a 0.71 increase in the ES estimate
for the primary efficacy endpoint (ie, an increase of
approximately seven-tenths of a standard deviation in
the primary efficacy endpoint). The associations were
statistically significant (P<0.001) for mean differences
in total score, marginally significant for bowel and
systemic symptoms domains (P=0.074 and P=0.101,
respectively), and not significant for emotional or
social function domains (P=0.20 for both).
Meta-Analysis of Other Categorical Moderator
Variables: Additional meta-analyses were conducted
for treatment comparisons of mean change in IBDQ-32
198 JPCRR • Volume 7, Issue 2 • Spring 2020

total scores across other categorical moderator variables
for which there were at least 2 included treatment
comparisons per category. These analyses found no
differences in pooled ES estimates as a function of
treatment type (biologic [n=9; ES: 0.54, 95% CI: 0.35,
0.72] vs small-molecule [n=4; ES: 0.38, 95% CI: 0.10,
0.66]; P=0.370), treatment duration (6 weeks [n=6; ES:
0.49, 95% CI: 0.28, 0.71] vs 8 weeks [n=5; ES: 0.54,
95% CI: 0.33, 0.76]; P=0.743), or baseline disease
severity (mild-to-moderate [n=4; ES: 0.68, 95% CI:
0.31, 1.05] vs moderate-to-severe [n=11; ES: 0.54, 95%
CI: 0.36, 0.72]; P=0.508). Heterogeneity was moderate
to high within most subgroups for each of these
moderator variable analyses (I2 values ranged from
63.3% to 86.6% for all subgroups except for those for
studies with an 8-week treatment duration [I2=11.4%]).
Sensitivity Analysis
All Treatment Arms Included: Sensitivity metaanalyses were conducted when combining IBDQ-32
outcomes across all reported treatment arms (not just the
treatment arms of the target dose) from studies described
in the 14 articles included in the primary analysis.
Pooled ES estimates and 95% CI for treatment
comparisons of IBDQ-32 outcomes in this sensitivity
analysis are presented in online-only Supplemental Table
S5. Relative magnitudes of pooled Hedges’ g estimates
were generally similar to those observed in the primary
analyses. Differences in pooled ES for IBDQ-32 total
scores were statistically significant between efficacious
studies, for which there was a medium-sized effect (ES:
0.64, 95% CI: 0.48, 0.80), and non-efficacious studies,
for which there was a small effect (ES: 0.27, 95% CI:
0.02, 0.51); Q(1): 6.3; P=0.012. As in the primary
analysis, high heterogeneity was observed among
efficacious studies (I2=76.6%) while there was very little
heterogeneity among non-efficacious studies (I2=0.6%).
Further, statistically larger ES for efficacious studies
than non-efficacious studies were found for differences
in change scores for 3 of the 4 IBDQ-32 domains:
systemic symptoms, emotional function, and social
function (P<0.10 for all).
High-Risk-of-Bias Studies Included: Sensitivity metaanalyses were conducted when including the high-riskof-bias study29 (n=15 articles) in meta-analytic models
based on target treatment arms.
Review

Figure 3. Forest plot for treatment comparisons of mean differences in Inflammatory Bowel Disease

Questionnaire (IBDQ-32) bowel symptom domain scores for efficacious and non-efficacious treatments. Pooled
effect estimates were calculated based on random-effects models, with relative weights for individual comparisons
based on inverse variance. The diamond represents a pooled effect estimate for each treatment efficacy subgroup.
Data are Hedges’ g with 95% confidence intervals.

Figure 4. Forest plot for treatment comparisons of mean differences in Inflammatory Bowel Disease

Questionnaire (IBDQ-32) systemic symptom domain scores for efficacious and non-efficacious treatments. Pooled
effect estimates were calculated based on random-effects models, with relative weights for individual comparisons
based on inverse variance. The diamond represents a pooled effect estimate for each treatment efficacy subgroup.
Data are Hedges’ g with 95% confidence intervals.
Review
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Figure 5. Forest plot for treatment comparisons of mean differences in Inflammatory Bowel Disease

Questionnaire (IBDQ-32) emotional function domain scores for efficacious and non-efficacious treatments. Pooled
effect estimates were calculated based on random-effects models, with relative weights for individual comparisons
based on inverse variance. The diamond represents a pooled effect estimate for each treatment efficacy subgroup.
Data are Hedges’ g with 95% confidence intervals.

Figure 6. Forest plot for treatment comparisons of mean differences in Inflammatory Bowel Disease

Questionnaire (IBDQ-32) social function domain scores for efficacious and non-efficacious treatments. Pooled
effect estimates were calculated based on random-effects models, with relative weights for individual comparisons
based on inverse variance. The diamond represents a pooled effect estimate for each treatment efficacy subgroup.
Data are Hedges’ g with 95% confidence intervals.
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Table 3. Results From Primary Meta-Regression Analysis
Outcome Model
Total score
Bowel symptoms
Systemic symptoms
Emotional function
Social function

Number of
Comparisons

Coefficient for
Treatment Efficacy*

Standard
Error

Z-Score

P

16
5
5
5
5

0.71
0.45
0.41
0.32
0.32

0.18
0.25
0.25
0.25
0.25

3.96
1.79
1.64
1.29
1.30

<0.001
0.074
0.101
0.196
0.195

*Based on Hedges’ g effect size for treatment effects on primary efficacy variable.

Pooled ES estimates and 95% CI for treatment
comparisons of IBDQ-32 outcomes in this sensitivity
analysis are presented in online-only Supplemental
Table S6. Relative magnitudes of pooled Hedges’ g
estimates for differences in IBDQ-32 total scores were
similar to those observed in the primary analyses, with
a statistically significantly larger effect for studies with
efficacious treatment (ES: 0.67, 95% CI: 0.51, 0.83)
than for studies with non-efficacious treatments (ES:
0.26, 95% CI: 0.01, 0.52; Q(1): 6.99; P<0.001). Pooled
estimates of Hedges’ g for mean differences for bowel
symptoms, systemic symptoms, and social function
domain scores for efficacious studies were mediumsized and statistically larger than zero (ES range:
0.50 to 0.58; P<0.001 for all) but for non-efficacious
studies were small and not statistically different from
zero (ES range: 0.08 to 0.25, P>0.10 for all), with the
pooled ES estimate statistically significantly larger for
the efficacious than non-efficacious studies for the 3
domains (P<0.10 for all).
The pooled estimate of Hedges’ g for mean differences
in emotional function domain scores for efficacious
studies was medium-sized and statistically larger than
zero (ES: 0.49, 95% CI: 0.37, 0.60; P<0.001). For nonefficacious studies it was small and not significantly
different from zero (ES: 0.24, 95% CI: -0.09, 0.58;
P=0.148), although the pooled ES estimate did not
statistically differ between the efficacious and nonefficacious studies for this domain (Q(1): 1.86;
P=0.172).
Publication Bias
Evaluation of publication bias was conducted for
treatment comparisons of mean differences in IBDQ32 total scores for the primary analyses, which
Review

included 13 of the 14 articles (93%) and 16 of the
19 comparisons (84%). Visual examination of the
funnel plot (online-only Supplemental Figure S4) and
results from Egger’s regression test (2-tailed P=0.888)
indicated that publication bias was unlikely an issue
of concern for this meta-analysis.

DISCUSSION

To the best of our knowledge, this paper provides the first
systematic literature review and synthesis of evidence
regarding the sensitivity of the IBDQ-32 to treatment
for UC. Specifically, the objective of this study was to
examine the impact of efficacious treatment on mean
change in IBDQ-32 outcomes. We defined treatment
efficacy both as a dichotomous variable, based on
success of meeting the primary study endpoint, and
also as a continuous variable, by calculating an ES
estimate for the treatment efficacy of that endpoint. For
both of these approaches, results were pooled across
studies reported in 14 published articles to investigate
whether treatment efficaciousness was a predictor of
change in IBDQ-32 total and domain scores.
For the dichotomous efficacy approach, the
primary meta-analysis found that patients in studies
with efficacious treatments showed larger mean
improvements relative to controls in IBDQ-32 total
scores and all 4 domains. At the same time, patients
in studies with non-efficacious treatments showed
small and nonsignificant differences in these outcomes
relative to controls. For the continuous efficacy
approach, the primary meta-regression models showed
that the magnitude of treatment efficacy was a positive
predictor of these same IBDQ-32 outcomes. Results
from sensitivity meta-analyses (of 15 articles) were
generally supportive of findings from the primary
www.aurora.org/jpcrr
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analysis. Thus, this disease-specific patient-centered
measure of HRQoL showed strong correspondence to
changes in clinical health as a function of treatment
interventions.
Meta-analyses were conducted to examine evidence
that effects for treatment comparisons of mean
changes in IBDQ-32 total score were associated with
potential moderator variables, including treatment
type, treatment duration, and severity of patients’
baseline disease activity. No differences in pooled
ES estimate across subgroups were found for any of
these factors. High heterogeneity was found across
ES estimates within most of these subgroups, which
may be due to the fact that each subgroup contained
a mix of efficacious and non-efficacious studies,
across which there were established differences in
ES magnitude. In the primary meta-analysis, high
heterogeneity also was observed across ES estimates
for mean changes in IBDQ-32 total scores within the
subgroup of efficacious studies. Even when removing
a study with an outlying ES relative to the rest within
the subgroup, a moderate amount of heterogeneity
was still observed. Within this subgroup, there were
a number of key differences among studies, including
factors such as types of treatments administered, type
of disease activity index measure used to capture
clinical efficacy, treatment duration, baseline severity
of UC, and potentially demographic factors. While
moderator analyses found that some of these factors
did not explain statistically significant differences in
ES estimates across studies, other factors varied too
greatly among studies to combine into meaningful
subgroups. The combined and possibly interactive
impacts of each of these factors on heterogeneity
in ES estimates cannot be easily assessed given the
limited number of studies.
The current analysis focused on the inclusion of the
IBDQ-32 in studies of patients with UC. However,
the IBDQ-32 is often included as an HRQoL endpoint
in studies of patients with Crohn’s disease.9 While
UC and Crohn’s disease are often studied together,
they represent distinct pathophysiological entities.44,45
Because our a priori research interest was in UC, it
would have been beyond the scope of our research
question to explore Crohn’s disease in this study. We
predict that if the same type of meta-analysis was
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conducted for studies using the IBDQ-32 with patients
with Crohn’s disease, the results would be similar to
those reported here for UC. In the absence of such
data, however, we defer to future research to answer
whether our results also apply to Crohn’s disease.
The primary reason for including the IBDQ-32 as a key
secondary endpoint in clinical trials is that it enables
a broader interpretation of treatment benefit. When
asked to describe their experiences with the disease,
patients with UC often mention clinical symptoms that
are typically assessed using disease activity indices.
Nevertheless, these patients also express concerns about
their disease and its impact on their everyday lives
that go far beyond what is captured by those indices.
They report anxieties stemming from a lack of control
over their bodily functions, fear of disease progression,
hospitalization or surgery, and fear of not having
immediate access to a toilet.46-48 These concerns impact
their employment opportunities and work productivity
and limit their ability to engage in social and recreational
activities, which can impair their ability to develop and
maintain relationships with others and subsequently
lead to difficulties achieving intimacy and to feelings of
isolation and depression.46,47,49-51 Thus, comprehensively
evaluating benefits of a treatment for patients with
UC entails more than merely assessing changes in
clinical and endoscopic activity — it also requires
measuring changes in patient-reported HRQoL. The
results provided here support the use of the IBDQ-32
to capture treatment benefits on functioning and wellbeing in patients with UC.
Limitations
A limitation of this study is that the literature search was
restricted to papers published in peer review journals,
with findings in the “gray” literature (eg, conference
presentations) not represented. Given that our study
objective was to evaluate what is typically used as
a secondary outcome measure, and not to provide
evidence supporting efficacy of any particular treatment
regimen, we believe that publication bias would be less
impactful for our review and that the consequences of
possible bias would be relatively low. As the ratio of
efficacious treatments to non-efficacious treatments
was fairly even (10:9), evidence from our examination
of publication bias shows that it is unlikely that an
exhaustive search of unpublished studies meeting our

Review

selection criteria would result in substantially different
findings than those observed here.
Another limitation of our review stems from the
decision to restrict our data sources to only randomized
controlled trials, such that our review and meta-analysis
did not include data on changes in IBDQ-32 scores from
interventional studies of patients with UC that used other
study designs, such as single-arm or nonrandomized
comparative designs. This decision was made because
the design of randomized controlled trials reduces
bias by minimizing confounds between patient groups
(due to randomization) and by controlling for placebo
effects on HRQoL, which have been demonstrated to be
substantial in studies of patients with UC.52 However,
by restricting our evidence base to only randomized
controlled trials, we limit the generalizability of our
findings and ignore data that could be relevant to the
question of the degree to which IBDQ-32 scores are
sensitive to the clinically efficacious UC treatments.
Future research incorporating findings from studies
using nonrandomized design could potentially provide
additional information with respect to the research
questions addressed in this review.
Another potential limitation of this analysis was a lack
of uniformity in determining whether or not a treatment
was efficacious. We relied on each study’s authors for
the determination about whether the primary efficacy
endpoint was met, according to the a priori definition
for that study. The fact that many studies used similar
definitions of efficacy (ie, significant mean difference
between target and placebo groups on a disease activity
measure, difference in proportion achieving response
or remission as defined by changes on disease activity
indices) reduced the potential variability in these
definitions across studies. The lack of overlap in ES
estimates for non-efficacious and efficacious target
treatments (Hedges’ g ranging from -0.75 to 0.42
and from 0.43 to 1.66, respectively) supports that the
dichotomous classification fairly represented actual
treatment efficacy.

CONCLUSIONS

This review provides new evidence that IBDQ-32
total and domain scores are sensitive and specific
to efficacious treatment, such that treatments that
effectively produced reduction of clinical and
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endoscopic UC symptoms also produced improvements
in IBDQ-32 scores, while treatments that did not
reduce UC disease activity did not produce substantial
changes in IBDQ-32 outcomes. Integrating these
findings with those from reviews providing evidence
for the reliability, validity, and responsiveness of
the IBDQ-32 for measuring IBD-specific HRQoL in
patients with UC7,8,11,12 supports the appropriateness
of including this instrument in clinical trials.

Patient-Friendly Recap
• Research studies on ulcerative colitis often
use a tool called the Inflammatory Bowel
Disease Questionnaire (IBDQ-32) to measure
changes in a patient’s health-related quality of
life following treatment. However, this tool has
not been validated as useful in randomized
clinical trials.
• The authors reviewed published results
from 14 randomized controlled trials that
used the IBDQ-32 in this patient population
to determine whether the tool performed to
expectations.
• They found that IBDQ-32 scores do indeed
reflect changes from treatment, supporting
the use of this tool to capture quality-of-life
outcomes in patients participating in ulcerative
colitis clinical trials.
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